EUVIMEDEUVIMED entdecken
VergleichsstudieRandomisierte kontrollierte StudieOpen Access · CC BY 4.0

Tacrolimus versus hydrocortisone in management of atopic dermatitis in children, a randomized controlled double‐blind study: New insights on TARC, CTACK, TSLP, and E‐selectin

Ammena Y Binsaleh, Fedaa A Kotkata, Mostafa M Bahaa iD, Amir O Hamouda, Mohamad A El-Gammal, Aya Ibrahim Elberri, Hend Mostafa Selim, Marwa Ahmed El-Samongy, Manal A Hamouda, Fatma A Mokhtar, Sherif Ashraf Fahmy, Thanaa A Elmasri und 1 weitere

Immunity, Inflammation and Disease · 2024

DOI: 10.1002/iid3.70028 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Immunity, Inflammation and Disease, 2024. Verfasst von Ammena Y Binsaleh und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Hydrocortisone, Tacrolimus. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: None.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Atopic dermatitis (AD) is a type of chronic inflammatory disorder that affects all age groups including children. AD is characterized by elevated inflammatory marker levels.

Aim

To assess the safety and effectiveness of topical tacrolimus ointment versus topical hydrocortisone cream in the treatment of pediatric AD by comparing the two treatments' ability to reduce serum cytokines. Patients and Methods One hundred AD patients who fulfilled the eligibility criteria completed this clinical study. Two groups of 50 AD patients each were selected from Tanta University's Dermatology Department., Group 1 (the hydrocortisone group) was administered topical hydrocortisone cream for a duration of 4 months. For 4 months, Group 2 was administered tacrolimus topically. Serum levels of thymus and activation regulated chemokine (TARC), cutaneous T cell attractant chemokine (CTAC), interleukin‐10 (IL‐10), interleukin‐6 (IL‐6), E selectin (E‐selectin), and thymic stromal lymphopoietin (TSLP) were measured during an evaluation of the patients by a dermatologist at the beginning and 4 months after the treatment had been started. Children's Dermatology Life Quality Index was used to assess quality of life in these patients.

Results

With the exception of E‐selectin, IL‐6, and IL‐10 ( p > .05), the tacrolimus group had a significant reduction in TARC, CTACK, TSLP ( p < .05) when compared to its baseline and when compared to the hydrocortisone group. Both groups showed a significant improvement in quality of life but no significant changes between groups were observed.

Conclusion

In children with AD, tacrolimus reduces inflammatory biomarkers better than hydrocortisone.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicHydrocortisoneTacrolimusAdolescentChildChild, PreschoolFemaleHumansMaleAdministration, TopicalAnti-Inflammatory AgentsBiomarkersChemokine CCL17Chemokine CCL27CytokinesDouble-Blind MethodE-SelectinImmunosuppressive AgentsQuality of LifeThymic Stromal LymphopoietinTreatment Outcome

Stichwörter der Autor:innen

CTACKE‐selectinTRACatopic dermatitishydrocortisonetacrolimus

Substanzen

Anti-Inflammatory AgentsBiomarkersCCL17 protein, humanChemokine CCL17Chemokine CCL27CytokinesE-SelectinHydrocortisoneImmunosuppressive AgentsTacrolimus

Autor:innen und Institutionen

  • Department of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
  • Department of Clinical Pharmacy, Faculty of Pharmacy, Tanta University, Tanta, Al-Gharbia, Egypt.
  • Pharmacy Practice Department, Faculty of Pharmacy, Horus University, New Damietta, Egypt.
  • Pharmacology and Biochemistry Department, Faculty of Pharmacy, Horus University, New Damietta, Egypt.
  • Department of Zoology, Genetic Engineering and Molecular Biology Division, Faculty of Science, Menoufia University, Shebin El-Kom, Menoufia, Egypt.
  • Biochemistry Department, Faculty of Pharmacy, Tanta University, Tanta, Al-Gharbia, Egypt.

ORCID-Profile: Mostafa M Bahaa

Förderung

  • None

Zitieren

APA

Binsaleh, A. Y., Kotkata, F. A., Bahaa, M. M., Hamouda, A. O., El-Gammal, M. A., Elberri, A. I., Selim, H. M., El-Samongy, M. A., Hamouda, M. A., Mokhtar, F. A., Fahmy, S. A., Elmasri, T. A., & Elberri, E. I. (2024). Tacrolimus versus hydrocortisone in management of atopic dermatitis in children, a randomized controlled double‐blind study: New insights on TARC, CTACK, TSLP, and E‐selectin. Immunity, Inflammation and Disease. https://doi.org/10.1002/iid3.70028

Vancouver

Binsaleh AY, Kotkata FA, Bahaa MM, Hamouda AO, El-Gammal MA, Elberri AI, et al. Tacrolimus versus hydrocortisone in management of atopic dermatitis in children, a randomized controlled double‐blind study: New insights on TARC, CTACK, TSLP, and E‐selectin. Immunity, Inflammation and Disease. 2024. doi:10.1002/iid3.70028

BibTeX
@article{Binsaleh2024,
  author = {Binsaleh, Ammena Y and Kotkata, Fedaa A and Bahaa, Mostafa M and Hamouda, Amir O and El-Gammal, Mohamad A and Elberri, Aya Ibrahim and Selim, Hend Mostafa and El-Samongy, Marwa Ahmed and Hamouda, Manal A and Mokhtar, Fatma A and Fahmy, Sherif Ashraf and Elmasri, Thanaa A and Elberri, Eman I},
  title = {Tacrolimus versus hydrocortisone in management of atopic dermatitis in children, a randomized controlled double‐blind study: New insights on TARC, CTACK, TSLP, and E‐selectin},
  journal = {Immunity, Inflammation and Disease},
  year = {2024},
  doi = {10.1002/iid3.70028}
}
Kostenlos starten →